Compare AVXL & DBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | DBI |
|---|---|---|
| Founded | 2004 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.1M | 375.2M |
| IPO Year | 2013 | 2005 |
| Metric | AVXL | DBI |
|---|---|---|
| Price | $3.40 | $7.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.00 | $6.75 |
| AVG Volume (30 Days) | ★ 2.0M | 798.0K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | N/A | ★ 2.74% |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,892,671,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | $1.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.61 | $2.18 |
| 52 Week High | $13.99 | $8.75 |
| Indicator | AVXL | DBI |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 71.02 |
| Support Level | $2.93 | $7.15 |
| Resistance Level | $4.88 | $7.59 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | 0.06 | 0.22 |
| Stochastic Oscillator | 98.62 | 96.26 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.